|Articles|March 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2001
  • Volume 0
  • Issue 0

Research: New Horizons

Author(s)Kevin Gopal

London, UK-Changes to the law on human embryo research could herald a new era for UK biotech research. The government feared its proposals to allow the cloning of embryos as sources for stem cells for research would be thrown out by the House of Lords-where a powerful body of opinion holds that they represent a slippery slope toward reproductive cloning-but the proposals passed by a surprisingly large majority.

Articles in this issue

over 25 years ago

Earnings: Tough Times Ahead

over 25 years ago

Outbreak: Anthrax Alarm

over 25 years ago

Patents: China on the Genome Map

over 25 years ago

Privacy, Pediatrics, and Policy

over 25 years ago

Lilly's International Family

over 25 years ago

Update: Punishment and Reprieve

over 25 years ago

Shortage: Vaccine Worries

over 25 years ago

Gateway to Japan

over 25 years ago

Surrounded

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.